NASDAQ:SCYX SCYNEXIS Q3 2026 Earnings Results & Report $3.41 -0.11 (-3.13%) Closing price 04:00 PM EasternExtended Trading$3.42 +0.00 (+0.15%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. SCYNEXIS beat analyst earnings expectations and met on revenue in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$0.71 versus the -$0.72 consensus estimate, while revenue of $130 thousand matched the $130 thousand estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeBefore Market OpensConference Call7:00 AM ET SCYNEXIS EPS ResultsActual EPS-$0.71Consensus EPS -$0.72Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersSCYNEXIS Revenue ResultsActual Revenue$130 thousandExpected Revenue$130 thousandBeat/MissMet ExpectationsYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) SCYNEXIS Q3 2026 Earnings FAQ Did SCYNEXIS beat earnings estimates for Q3 2026? SCYNEXIS (NASDAQ:SCYX) reported earnings of -$0.71 per share for Q3 2026, beating the consensus estimate of -$0.72. The report was announced on Thursday, November 5, 2026. What was SCYNEXIS' revenue for Q3 2026? SCYNEXIS reported revenue of $130 thousand for Q3 2026, against a consensus estimate of $130 thousand. SCYNEXIS Earnings HeadlinesSCYNEXIS Targets Year-End Kidney Drug Trial as Antifungal Program AdvancesNovember 10 at 4:13 AM | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) Cut to "Sell" at Wall Street ZenNovember 10 at 2:31 AM | americanbankingnews.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 11 at 1:00 AM | Behind the Markets (Ad)SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 5, 2026 | globenewswire.comComparing SCYNEXIS (NASDAQ:SCYX) and Zevra Therapeutics (NASDAQ:ZVRA)November 1, 2026 | americanbankingnews.comSCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation ConferenceOctober 29, 2026 | globenewswire.comSee More SCYNEXIS Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SCYNEXIS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SCYNEXIS and other key companies, straight to your email. Email Address About SCYNEXISSCYNEXIS (NASDAQ:SCYX) is a biotechnology company focused on developing and commercializing innovative antifungal therapies for the treatment of serious and common fungal infections. The company’s research platform is centered on ibrexafungerp, a novel triterpenoid antifungal designed to inhibit glucan synthase, an enzyme important to the formation of fungal cell walls. SCYNEXIS’s lead product, BREXAFEMME (ibrexafungerp tablets), is an oral antifungal approved in the United States for the treatment of vaginal yeast infections, also known as vulvovaginal candidiasis. It is also approved to reduce the incidence of recurrent vulvovaginal candidiasis in adult and postmenarchal adolescent females. Unlike azole antifungals, ibrexafungerp belongs to a different structural class and is being developed to address infections involving fungi that may be resistant to existing treatments. The company is also evaluating ibrexafungerp for additional indications, including certain invasive fungal infections, and has pursued opportunities to expand the product’s use through clinical development and commercial collaborations. SCYNEXIS is headquartered in Jersey City, New Jersey, and its principal commercial focus has been the United States, where BREXAFEMME is marketed for approved indications.View SCYNEXIS ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
